Association between visceral adiposity and generalized anxiety disorder (GAD)

• Published in: BMC Psychology Vol. 12; no. 1; p. 49
• Main Authors: Nameni, Ghazaleh, Jazayeri, Shima, Salehi, Masoud, Esrafili, Ali, Hajebi, Ahmad, Motevalian, Seyed Abbas
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.01.2024; BioMed Central; BMC
• Subjects: Adipose tissues; Adiposity; Analysis; Anxiety Disorders - epidemiology; Care and treatment; Chronic illnesses; Cohort Studies; Cross-sectional; Diagnosis; Female; GAD; Generalized anxiety disorder; Health aspects; Humans; Inflammation; Male; Measurement; Mental disorders; Psychology, Pathological; Risk Factors; Socioeconomic factors; Visceral adiposity; Womens health; Iran; GAD; Generalized anxiety disorder; Cross-sectional; Visceral adiposity
• ISSN: 2050-7283; 2050-7283
• DOI: 10.1186/s40359-024-01542-x

Due to an increased rate of inflammation in generalized anxiety disorder (GAD), insight into the mediating factors in the onset and recurrence of the inflammatory response can help to achieve novel treatments for alleviating the risk of GAD. In the current study, we aimed to evaluate the possible relationship between visceral adipose tissue (VAT) as an important intermediary in inflammation pathways and GAD in participants of the Employees' Health Cohort Study of Iran (EHCSIR). We analyzed the data from 3889 included participants aged > 18 years in the EHCSIR study, which were collected from 2017 to 2020. Lifetime and 12-month GAD were assessed using the Composite International Diagnostic Interview (CIDI-2.1) questionnaire. The adjusted prevalence ratio was computed to evaluate the association between GAD and visceral adiposity index (VAI), GAD and visceral fat area (VFA), GAD and body mass index (BMI) and ultimately GAD and waist circumference (WC) in males and females using STATA software. Log-binomial analysis showed a higher prevalence ratio of 12-month GAD associated with VFA in women [PR: 1.42, CI: 1.07-1.87, P: 0.015]. The prevalence of lifetime GAD was higher in obese women (BM1 > 30) [PR: 2.35, CI: 1.07-5.13, P:0.03] than in women with normal BMI. Women with higher VAI were also significantly more likely to suffer lifetime GAD [PR: 1.25, CI: 1.05]. 1.48, P:0.01]. In males, the prevalence of lifetime diagnosed GAD per 1 standard deviation increase in VFA was 0.65 [CI: 0.46-0.91, P: 0.01]. Visceral adiposity as a positive agent was associated with GAD prevalence in women. The presence of GAD symptoms showed no relationship to VFA in men.